ReviewExpert opinion on emerging drugs2015
Emerging drugs for the treatment of anxiety.
Review in Expert opinion on emerging drugs, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed.
- Neuroimaging Insights: Kava's (Nutrients · 2023Trial
- Prenatal Exposure to Anxiolytics: A Critical Review on Brain Development and Neurobehavioral Manifestations in Offspring.Neurotoxicity research · 2026Review
- Ultrasonic vocal communication of negative affective states in laboratory mice.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- A Review of Chronic Wounds and Their Impact on Negative Affect, Cognition, and Quality of Life.International wound journal · 2025Review
- Analysis of Anxiety Disorders and Post-Traumatic Stress Disorders for Screening Anxiolytic Drugs and Linking Preclinical and Clinical Research.International journal of molecular sciences · 2025Review
- Recent developments in intranasal drug delivery of nanomedicines for the treatment of neuropsychiatric disorders.Frontiers in medicine · 2024Review
- Monoamine Oxidase: A Potential Link in Papez Circuit to Generalized Anxiety Disorders.CNS & neurological disorders drug targets · 2024Review
- Playback of rat 22-kHz ultrasonic vocalizations as a translational assay of negative affective states: An analysis of evoked behavior and brain activity.Neuroscience and biobehavioral reviews · 2023Review
- Hippocampus: Molecular, Cellular, and Circuit Features in Anxiety.Neuroscience bulletin · 2023Review
- Variation along P2RX7 interacts with early traumas on severity of anxiety suggesting a role for neuroinflammation.Scientific reports · 2023Article
- Anxiolytic-like Effects and Quantitative EEG Profile of Palmitone Induces Responses Like Buspirone Rather Than Diazepam as Clinical Drugs.Molecules (Basel, Switzerland) · 2023Article
- Gut Microbiota in Anxiety and Depression: Unveiling the Relationships and Management Options.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Does Having Rheumatoid Arthritis Increase the Dose of Depression Medications? A Mendelian Randomization Study.Journal of clinical medicine · 2023Article
- Effects of Current Psychotropic Drugs on Inflammation and Immune System.Advances in experimental medicine and biology · 2023Article
- Biochemical and Pharmacological aspects ofBiochemistry and biophysics reports · 2022Article
- The Future of Targeted Treatment of Primary Sjögren's Syndrome: A Focus on Extra-Glandular Pathology.International journal of molecular sciences · 2022Review
- Review
- Whole-exome DNA sequencing in childhood anxiety disorders identifies rare de novo damaging coding variants.Depression and anxiety · 2022Article
- The potential mechanism of Bupleurum against anxiety was predicted by network pharmacology study and molecular docking.Metabolic brain disease · 2022Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
introductionAnxiety disorders are among the most prevalent and disabling psychiatric disorders in the United States and worldwide. Basic research has provided critical insights into the mechanism regulating fear behavior in animals and a host of animal models have been developed in order to screen compounds for anxiolytic properties. Despite this progress, no mechanistically novel agents for the treatment of anxiety have come to market in more than two decades. AREAS COVERED: The current review will provide a critical summary of current pharmacological approaches to the treatment of anxiety and will examine the pharmacotherapeutic pipeline for treatments in development. Anxiety and related disorders considered herein include panic disorder, social anxiety disorder, generalized anxiety disorder and post-traumatic stress disorder. The glutamate, neuropeptide and endocannabinoid systems show particular promise as future targets for novel drug development. EXPERT OPINION: In the face of an ever-growing understanding of fear-related behavior, the field awaits the translation of this research into mechanistically novel treatments. Obstacles will be overcome through close collaboration between basic and clinical researchers with the goal of aligning valid endophenotypes of human anxiety disorders with improved animal models. Novel approaches are needed to move basic discoveries into new, more effective treatments for our patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.